Phase II trial of rociletinib (CO 1686) in Japanese patients with non-small cell lung cancer

Trial Profile

Phase II trial of rociletinib (CO 1686) in Japanese patients with non-small cell lung cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2015

At a glance

  • Drugs Rociletinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 08 May 2015 New trial record
    • 06 May 2015 This phase II study in Japanese patients has been agreed upon by Japanese regulatory authorities and is expected to be initiated in the second half of 2015, according to a Clovis Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top